Horizon 2020 is the biggest EU Framework Programme for Research & Innovation ever with nearly €80 billion of funding available over 7 years (2014 to 2020). The main goal of the program is to lead to more breakthroughs and discoveries by taking great ideas from the lab to the market focusing on three key areas: excellent science, industrial leadership and societal challenges.
We are proud to announce that Comac Medical positioned Bulgaria on the map of the Horizon 2020 program with an innovative approach for early diagnosis and monitoring of inflammatory and degenerative processes in the lungs including but not limited to asthma, chronic obstructive pulmonary diseases (COPD), tuberculosis and lung cancer.
“You are among the companies with the most innovative ideas in the world.”
Marco Rubinato – Project Officer, European Commission – Executive Agency for SMEs (EASME)
In October 2015, Comac Medical has successfully completed Phase I SME Instrument Horizon 2020 project, on the topic: “Improving diagnostics of respiratory diseases and boosting the COMAC MEDICAL competitiveness and growth by validation of fractional EBT biomarker through a new method of measurement and device.” As a result, Comac Medical submitted a final report, containing the details and the results of the feasibility study which proved the commercial potential and significant innovativeness of the project idea. The final report was approved by the European Commission and on the basis of the successful completion of Phase I SME Instrument project, Comac Medical started the preparation of Phase II.
In addition, Comac Medical was assessed via IMP³rove – an instrument provided by the European Commission for measurement of the innovation potential of the company, which ranked Comac Medical among the ‘Growth Champions’ in Europe. The IMP³rove Assessment report from October 19, 2015, which is a valuable indication of the SME competitive position, shows the positive innovation management performance of Comac Medical, which is the same with the ‘Growth Champions’, with an overall score of 58% in a benchmarking class of all countries and above the average score of 54%.
In February 2016 Comac Medical has received a certificate ‘Seal of Excellence’ for Horizon 2020 SME Instrument Phase II Project Proposal. It was delivered by the European Commission as the institution managing Horizon 2020. The so-called – Seal of Excellence is a quality label, awarded to project proposals submitted for funding under Horizon 2020.
The project proposal of Comac Medical has been classified by the European Commission as highly innovative which coincides with the conclusions of the final report from Phase I. The report states the considerable novelty and commercial potential of the validation of SB-FrEBT biomarker through a new medical device. The proposed innovative solution by Comac Medical is a response:
• On the one hand to the EU wide and global challenges related to the respiratory diseases, causing a high level of morbidity and mortality especially among the most vulnerable groups of young and elder people (about 1million deaths annually in the European Region; 2/3 of them in EU28, with total cost there of €380bln.)
• On the other hand to the implementation of the Innovation strategy for smart specialization of the Republic of Bulgaria (2014-2020) through the country’s progress in the thematic priorities – biotechnological industry, healthy living industry, and pharmacy.
Comac Medical’s qualification for Horizon 2020 beneficiary is a unique success. It came as a result of our team motivation, expertise and ambition to gain knowledge. This recognition also shows our training and ability to execute projects under the Horizon 2020 European Program for Research and Innovation, and the European structural and investment funds. We prove that we are able to generate significant economic innovations that affect global healthcare in a highly positive manner.